Status:
UNKNOWN
Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis
Lead Sponsor:
University of Kiel
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
Respiratory und intestinal microbiome will bei analyzed during a period of 6 months. In a retrospective analysis it will be looked for correlations between microbiome and cf therapy (e.g. inhaled and ...
Detailed Description
DNA will be isolated from sputum, throat swabs and stool samples and used for the generation of microbial profiles. Both bacterial and fungal profiles will be analyzed by next generation sequencing. ...
Eligibility Criteria
Inclusion
- subject has confirmed diagnosis of cystic fibrosis (sweat chloride \>60mmol/l and/or 2 mutations in the cftr gene known to cause cystic fibrosis)
- subject is able to perform informed consent
Exclusion
- inability to give informed consent
- antibiotic therapy in the last 4 weeks prior to study start (exception: long term azithromycin therapy, long term antistaphylococcal therapy, long term inhaled antibiotics)
Key Trial Info
Start Date :
September 28 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT03335202
Start Date
September 28 2017
End Date
September 1 2020
Last Update
November 17 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinik für Innere Medizin I, UKSH KIel
Kiel, Schleswig-Holstein, Germany, 24105